rivoceranib
hlb bio group,Elevar Therapeutics
['rivoceranib']
elevar therapeutics detailed the results of its phase 2 clinical trial of rivoceranib, an orally administered tyrosine kinase inhibitor, in patients with progressive recurrent or metastatic adenoid cystic carcinoma at the asco annual meeting. #biohive 
BioHive is a collective representing the life science & healthcare innovation ecosystem of Utah’s economy. Share your story and tag #BioHive